Science, Innovation, Creativity, Serendipity in Medicine

MOLECULAR MOLECULES is a research-based, clinical-stage specialty biopharmaceutical company focused on the discovery, development and commercialization of novel products for all global medicine markets. Our objective is to develop first-in-class, highly profitable, over-the-counter and prescription products using an approach that demands scientific rigor of biotechnology, sociology, chemistry, psychiatry, genomics, proteomics, metabolomics and fashionomics to address unmet needs in the rapidly-growing market for medicine. Our initial focus is on a growing threat to pharmaceutical corporate executives around the world: PCFS (Permanently Crossed Fingers Syndrome). We expect the foundational IP behind this protein therapeutic will inform our future treatment indications. Since we have an extremely diverse technology platform upon which to build, we will be announcing high impact products in the near term that promise to be appealing to non-discriminating investors.
​

In The Pipeline

Our first product candidate, MMX-109, is a potential first-in-class, topically applied drug currently in clinical testing in an undisclosed third world country for controlling PCFS (Permanently Crossed Fingers Syndrome) which commonly presents as an undesirable inability to 'uncross fingers'. Usually seen at high levels of the pharmaceutical industry, this devastating syndrome is embarrassing when patients are forced to attend cocktail parties, where holding drinks and shaking hands are the norm. Molecular Molecules maintains a highly focused research interest in developing products that affect very important people with deep products.
​

Our Regulatory Strategy

With global demands for more focused and efficacious medicinal products, Molecular Molecules expects to routinely introduce products that perform better than the typical new therapeutic on the market. Our plan includes new and novel molecules and technologies, with just enough testing (JET) to be certain the product performs to specifications. Why JET? Because we plan to save millions of dollars on needless clinical testing and use the savings to defend against litigious parties. We have plans to introduce products which will revolutionize medicine, but since we make no official claims as to disease cure, diagnosis or treatment, we will bypass the very expensive and time consuming regulatory requirements for medicine.